Patents by Inventor Julia Kubanek

Julia Kubanek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pentagalloyl Glucose Derived from Schinus Plants and Methods of Use
    Publication number: 20230112887
    Abstract: This disclosure relates to pentagalloyl glucose compositions and uses in managing microbial infections and compositions related thereto. In certain embodiments, this disclosure relates to compositions of pentagalloyl glucose. In certain embodiments, this disclosure relates to methods of treating or preventing a microbial infection, e.g., an antimicrobial resistant microbial infection, comprising administering to a subject in need thereof an effective amount of pentagalloyl glucose or salt thereof. In certain embodiments, the microbe is bacteria or fungi resistant to one or more antibiotic agents or antifungal agents.
    Type: Application
    Filed: February 26, 2021
    Publication date: April 13, 2023
    Inventors: Cassandra Quave, Francois Chassagne, Lewis Marquez, Micah Dettweiler, Julia Kubanek, Anne M. Sweeney-Jones, Bhuwan Khatri Chhetri
  • Methods for inhibiting CLC-2 channel with GATX2
    Patent number: 8324158
    Abstract: Compositions and methods of using scorpion venom peptide that is a ligand for ClC channels are provided. One aspect provides a pharmaceutical composition containing an amount of GaTx2 effective to inhibit ClC activity. Methods of treating a disorder or symptom of a disorder related to aberrant ClC channel activity are also provided.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: December 4, 2012
    Assignee: Georgia Tech Research Corporation
    Inventors: Neal McCarty, Christopher H. Thompson, Julia Kubanek
  • ABC transporter ligand GATX1
    Patent number: 8106013
    Abstract: Compositions and methods of using scorpion venom peptide that is a ligand for ABC transporters. One aspect provides a peptide having at least 80% sequence identity to SEQ ID NO: 1. The peptide Is believed to have a molecular mass of about 3.7 kDa and specifically interacts with cystic fibrosis transmembrane conductance regulator. Methods of treating a disorder or symptom of a disorder related to aberrant ABC transporter activity are also provided.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: January 31, 2012
    Assignee: Georgia Tech Research Corporation
    Inventors: Nael McCarty, Matthew Fuller, Julia Kubanek
  • CLC Channel Ligand
    Publication number: 20090239800
    Abstract: Compositions and methods of using scorpion venom peptide that is a ligand for ClC channels are provided. One aspect provides a pharmaceutical composition containing an amount of GaTx2 effective to inhibit ClC activity. Methods of treating a disorder or symptom of a disorder related to aberrant ClC channel activity are also provided.
    Type: Application
    Filed: July 12, 2007
    Publication date: September 24, 2009
    Inventors: Nael McCarty, Christopher H. Thompson, Julia Kubanek
  • ABC TRANSPORTER LIGAND
    Publication number: 20090203598
    Abstract: Compositions and methods of using scorpion venom peptide that is a ligand for ABC transporters. One aspect provides a peptide having at least 80% sequence identity to SEQ ID NO: 1. The peptide Is believed to have a molecular mass of about 3.7 kDa and specifically interacts with cystic fibrosis transmembrane conductance regulator. Methods of treating a disorder or symptom of a disorder related to aberrant ABC transporter activity are also provided.
    Type: Application
    Filed: May 18, 2007
    Publication date: August 13, 2009
    Applicant: GEORGIA TECH RESEARCH CORPORATION
    Inventors: Nael McCarty, Matthew Fuller, Julia Kubanek